Dermata Therapeutics Inc [NASDAQ: DRMA] jumped around 1.37 points on Wednesday, while shares priced at $2.67 at the close of the session, up 105.38%.
Compared to the average trading volume of 87.18K shares, DRMA reached a trading volume of 65110554 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Dermata Therapeutics Inc [DRMA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DRMA shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DRMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Dermata Therapeutics Inc is set at 0.66 The Price to Book ratio for the last quarter was 0.31, with the Price to Cash per share for the same quarter was set at 6.86.
How has DRMA stock performed recently?
Dermata Therapeutics Inc [DRMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 34.20. With this latest performance, DRMA shares dropped by -7.29% in over the last four-week period, additionally sinking by -57.48% over the last 6 months – not to mention a drop of -88.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DRMA stock in for the last two-week period is set at 54.29, with the RSI for the last a single of trading hit 60.79, and the three-weeks RSI is set at 49.68 for Dermata Therapeutics Inc [DRMA]. The present Moving Average for the last 50 days of trading for this stock 2.9800, while it was recorded at 1.8400 for the last single week of trading, and 6.7700 for the last 200 days.
Dermata Therapeutics Inc [DRMA]: Deeper insight into the fundamentals
Dermata Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.78 and a Current Ratio set at 3.78.
Insider trade positions for Dermata Therapeutics Inc [DRMA]
The top three institutional holders of DRMA stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in DRMA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in DRMA stock with ownership which is approximately 5.1238%.
